San MediTech

San MediTech is a China-based medical device company focused on continuous glucose monitoring and diabetes management products. The company develops and markets dynamic glucose monitoring systems, biosensor-based CGM hardware, mobile-connected transmitters, hospital monitoring products, and cloud-based glucose data management tools. Its business appears centered on commercialized glucose-control products rather than a traditional therapeutic drug pipeline. San MediTech has been described as operating from Huzhou, China, with historical ties to a U.S.-linked holding structure through America-Asia Diabetes Research Foundation. The company was acquired in 2018 in a transaction involving Ossen Innovation, while public and company-profile sources still indicate ongoing operating status. Overall, it is best characterized as a commercial-stage diabetes device and digital monitoring company.